Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net income | $484M | $1.57B | $600M | $1.52B | $1.52B | $1.30B |
| EPS (diluted) | $1.14 | $3.51 | $1.19 | $2.68 | $2.44 | $1.86 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$580M | -$2.46B | -$1.36B | $511M | -$2.13B | -$1.72B |
| Share buybacks | $100M | $0.00 | $0.00 | — | — | — |
| Dividends paid | $679M | $694M | $912M | $1.03B | $1.14B | $1.26B |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $326M | $372M | $303M | $535M | $635M | $638M |
| Total assets | — | $20.8B | $22.4B | $23.8B | $28.3B | $31.2B |
| Total liabilities | — | $12.0B | $12.8B | $12.6B | $14.9B | $16.9B |
| Long-term debt | — | $11.0B | $12.2B | $11.9B | $13.7B | $16.0B |
| Shareholders' equity | $7.18B | $8.87B | $9.55B | $11.2B | $13.4B | $14.3B |
| Retained earnings | — | — | -$2.00M | $462M | $852M | $958M |
| Shares (wtd avg diluted) | 424M | 446M | 518M | 575M | 624M | 699M |
Every figure is extracted from ARES CAPITAL CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.